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Background: Combination therapy is a key strategy for minimizing drug resistance, a common problem in cancer
therapy. The microtubule-depolymerizing agent vincristine is widely used in the treatment of acute leukemia. In
order to decrease toxicity and chemoresistance of vincristine, this study will investigate the effects of combination
vincristine and vorinostat (suberoylanilide hydroxamic acid (SAHA)), a pan-histone deacetylase inhibitor, on human
acute T cell lymphoblastic leukemia cells.
Methods: Cell viability experiments were determined by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT) assay, and cell cycle distributions as well as mitochondria membrane potential were analyzed by
flow cytometry. In vitro tubulin polymerization assay was used to test tubulin assembly, and immunofluorescence
analysis was performed to detect microtubule distribution and morphology. In vivo effect of the combination was
evaluated by a MOLT-4 xenograft model. Statistical analysis was assessed by Bonferroni’s t test.
Results: Cell viability showed that the combination of vincristine and SAHA exhibited greater cytotoxicity with an
IC50 value of 0.88 nM, compared to each drug alone, 3.3 and 840 nM. This combination synergically induced G2/M
arrest, followed by an increase in cell number at the sub-G1 phase and caspase activation. Moreover, the results of
vincristine combined with an HDAC6 inhibitor (tubastatin A), which acetylated α-tubulin, were consistent with the
effects of vincristine/SAHA co-treatment, thus suggesting that SAHA may alter microtubule dynamics through
HDAC6 inhibition.
Conclusion: These findings indicate that the combination of vincristine and SAHA on T cell leukemic cells resulted
in a change in microtubule dynamics contributing to M phase arrest followed by induction of the apoptotic
pathway. These data suggest that the combination effect of vincristine/SAHA could have an important preclinical
basis for future clinical trial testing.
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Microtubules, dynamically structured polymers of α-
tubulin and β-tubulin, are required in many cellular
processes, including vesicle and organelle transporta-
tion, cellular motility, cell shape maintenance,
chromosome separation, and division [1]. Before cells* Correspondence: slpan@tmu.edu.tw; cmteng@ntu.edu.tw
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the cytosol. As the cell enters the M phase, however,
the original reticular microtubules are remodeled and
assembled into mitotic spindles, which connect with
chromosomes and drive chromosome separation [2].
All of the microtubule processes described above are
crucial for microtubule polymerization (stabilization)
and depolymerization (destabilization).
Drugs that inhibit microtubule dynamics have been
used clinically in cancer treatment for more than
20 years [3]. These agents can be divided into two
major types: microtubule-destabilizing agents, such as
vincristine, and microtubule-stabilizing agents, such asicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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affect only microtubule dynamics, inducing abnormal
mitotic spindle formation and causing cell arrest in
the M phase and, subsequently, cell apoptosis [5].
Microtubule-binding agents have played critical roles
in the history of chemotherapeutic drug development
and remain a first choice in the treatment of solid tu-
mors and hematological malignancies. As with other
anticancer agents, however, the problems of drug re-
sistance, neuropathy, immunosuppression, and poor
solubility must be addressed. The current trends in
tubulin-binding agent development are to change the
dosage to improve solubility or a combination of
these agents with other anticancer drugs to reduce
toxicity and enhance activity [6].
Histone deacetylase (HDAC) catalyzes the removal
of the acetyl group in histones and nonhistone pro-
teins. HDACs have different biological functions due
to the highly divergent sequences outside the cata-
lytic domain [7]. HDAC6, which predominates in the
cytoplasm [8], is responsible for tubulin deacetylation,
which plays a key regulatory role in the stability of
the dynamic microtubules [9–12]. HDAC overexpres-
sion in many cancers has also been reported [13–15].
Thus, HDAC is believed to be a promising target for
cancer therapy [16]. HDAC inhibitors (HDACis)
cause histone hyperacetylation, thus activating the si-
lenced gene for normal cellular function (cell cycle,
angiogenesis, immunoregulation, cell apoptosis) [17].
In addition, HDACis have been found to target non-
histone proteins, including protein 53 (p53), E2F1,
signal transducer and activator of transcription 1, nu-
clear factor-κβ, α-tubulin, heat shock protein 90, and
Ku 70 [18–20]. Suberoylanilide hydroxamic acid
(SAHA), a pan-HDACi, was the first HDACi ap-
proved by the FDA for cutaneous T cell lymphoma
in 2006 [21–23]. Owing to their low toxicity and
wide range of activity, HDACis are often combined
with other anticancer drugs [24]. Most studies have
been performed using cell-based experiments [23],
but many combination therapies are undergoing clin-
ical trials, often for hematological malignancies [17].
The purpose of this study is to evaluate the com-
bined effects of vincristine and SAHA on an acute T
cell lymphoblastic leukemia (ALL) model. We deter-
mined the mechanism underlying cell arrest in the
mitotic phase and subsequent apoptosis following
combination treatment. We found that vincristine and
SAHA have a synergic effect on microtubules through
different mechanisms. Moreover, this combined influ-
ence was also observed in in vivo results. Conse-
quently, we suggest that a vincristine and SAHA
combination treatment could be used in the clinical
setting.Results
Cytotoxic effects of vincristine and SAHA, alone and in
combination, on human leukemic MOLT-4 cells
A 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT) assay was performed to investigate
the cytotoxicity of the microtubule-destabilizing agent
vincristine and the HDACi vorinostat (SAHA) on hu-
man ALL MOLT-4 cells. We first tested the cytotoxic
effect of SAHA and vincristine alone and in combin-
ation. As shown in Fig. 1a, there was no significant
cytotoxicity at concentrations up to 500 nM of
SAHA. However, SAHA had an IC50 of 840 nM for
48 h, when concentration reached the highest level
(1000 nM). In addition, vincristine exhibited cytotox-
icity against human leukemic MOLT-4 cells with an
IC50 of 3.3 nM at 48 h (Fig. 1b). To determine
whether an interaction between SAHA and vincris-
tine took place, the cytotoxic potency of a combin-
ation assay was measured. Cells treated with 500 nM
SAHA and various concentrations of vincristine (0.3
to 3 nM) significantly inhibited cell survival com-
pared to each treatment alone (Fig. 1c).Effects of vincristine in combination with SAHA on human
T cell leukemic cell survival
To further explore the synergistic cytotoxic effects,
we determined the effects on cell cycle distribution.
As compared with SAHA, treatment with vincristine
induced an increase in the G2/M phase of the cell
cycle. In particular, the combination of vincristine
plus SAHA caused an almost complete arrest of cells
in the G2/M phase following short-term treatment
(24 h) and a subsequent induction in the sub-G1
phase following long-term treatment (48 h) (Fig. 2a).
Figure 2b shows the statistical results. Next, the com-
bination index (CI) method was used to evaluate the
synergistic combinations [25]. A CI value of >1.0, 1.0,
and <1.0 indicates an antagonistic, additive, or syner-
gistic interaction, respectively, between the drugs. In
the G2/M phase, the CI values of vincristine (0.3, 1,
and 3 nM) combined with 500 nM SAHA were 1.63,
0.72, and 0.32, respectively, and the CI values in the
sub-G1 phase were 0.97, 0.77, and 0.28, respectively
(Fig. 2c). And this synergistic combination effect also
was noted in the other T cell leukemic cell line,
CCRF-CEM (Fig. 2d), rather than in acute myeloid
leukemic cells (Additional file 1: Figure S2). Moreover,
vincristine (1 or 3 nM) combined with various con-
centrations of SAHA also shows synergistic effect
(Additional file 2: Figure S1). These data indicate that
vincristine and SAHA synergistically induced cell ar-
rest in the G2/M phase and subsequently in the sub-
G1 phase.
Fig. 1 Cell viability effects of SAHA or vincristine alone and in combination on the MOLT-4 cell line. Cell viability was measured by MTT assay. a, b
MOLT-4 cells were treated with various concentrations of SAHA and vincristine alone for 24 and 48 h, respectively. c The combination of SAHA (S) and
vincristine (V) was compared to the effect of vincristine alone. Data are expressed as mean values ± SD of at least three separate determinations.
*P < 0.05, ** P < 0.02, *** P < 0.005
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Fig. 2 The combination of vincristine and SAHA had synergic effects on cell cycle kinetic changes. a MOLT-4 cells were treated with various concentrations
of vincristine alone or in combination with SAHA (500 nM) for 24 and 48 h. b The quantitative data are shown in the time course. Cell cycle distribution
was performed by cell cytometry after propidium iodide staining. c The combination effect of SAHA (500 nM) and vincristine (0.3, 1, and 3 nM) on G2/M
arrest (left figure) and apoptosis (right figure) were used by the combination index (CI). And the CI was analyzed with the program CompuSyn (Ting-Chao
Chou and Nick Martin). A CI value <1 represents that two drugs have synergic effects. d CCRF-CEM cells were treated with the indicated concentrations of
vincristine alone or in combination with SAHA (1000 nM) for 48 h. The effect of sub-G1 phase was analyzed by flow cytometry. Data are expressed as mean
values ± SD of at least three separate determinations. Fa fraction affected, S SAHA, V vincristine
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arrest in human leukemic MOLT-4 cells
To further elucidate the synergistic effect mechanism on
the G2/M phase of cell cycle progression, we investigated
SAHA in combination with vincristine on tubulin
polarization change and mitosis-related proteins. As
shown in Fig. 3a, there were no obvious tubulin
polarization changes following SAHA treatment under
cell-free conditions. However, in combination with
vincristine, a significant induction of microtubule
depolymerization was observed (Fig. 3a). Additional file
3: Figure S3 shows a more comprehensive result, in-
cluding various vincristine- and SAHA-alone in vitro
tubulin polymerization assays. To understand the ef-
fects of microtubule dynamics on mitosis following
drug treatment, the microtubule arrangement in hu-
man leukemic MOLT-4 cells was examined by β-
tubulin staining. As shown in Fig. 3b(b), there was no
significant change in microtubule distribution and cell
morphology after SAHA treatment. In addition, at
low vincristine concentrations, cells had accumulated
at the metaphase stage of mitosis with abnormal
spindles (Fig. 3b(c)). In this study, spindles with
bipolar and multipolar organization, which had
abnormal long astral microtubules and chromosomes,
were found to be unequally distributed. Nevertheless,
at a high vincristine concentration, microtubule
depolymerization was observed (Fig. 3b(d)). In the
present study, the vincristine and SAHA combination
exerted more explicit effects than vincristine alone
with regard to abnormal spindles and chromosomes
(Fig. 3b and Additional file 4: Figure S4). These re-
sults suggest that SAHA potentiated the effects of
vincristine due to inhibition of microtubule dynamics.
M phase-regulating proteins were also analyzed.
The combination of various concentrations of vincris-
tine (0.3, 1, and 3 nM) with SAHA (500 nM) for
24 h increased the phosphorylation of two mitotic
markers (MPM2 and H3S10) in a concentration-
dependent manner. These results proved that the
combination of vincristine and SAHA induced M
phase arrest. Moreover, vincristine in combination
with SAHA also induced mitotic arrest by stimulating
cyclin B1, aurora B, phospho-Cdc2 (Thr161), and
phospho-PLK1 expression, and suppressing Cdc25cand phospho-Cdc2 (Tyr15) levels. The magnitude of
these changes was more obvious than those observed
with vincristine treatment alone (Fig. 3c). These find-
ings demonstrate that SAHA enhanced vincristine-
induced M phase arrest and that the combination
therapy induced microtubule dynamics instability and
mitotic activation.
Effects of SAHA in combination with vincristine on the
apoptotic pathway and HDAC activity in human leukemic
MOLT-4 cells
Mitochondria play a crucial role both in the intrinsic
and extrinsic apoptotic pathways. To test whether the
vincristine/SAHA-mediated apoptotic pathway was asso-
ciated with mitochondrial function, a change in mito-
chondrial transmembrane potential (Δψm) was assessed.
As shown in Fig. 4a, treatment with SAHA or vincristine
alone was insufficient to affect the mitochondrial
membrane potential; however, this phenomenon was
enhanced by co-treatment with SAHA in a time-
dependent manner. The Bcl-2 protein family plays a
regulatory role in controlling the mitochondrial apop-
totic pathway. The data showed that the combination
treatment more effectively downregulated the expression
of the pro-survival members of the Bcl-2 family, such as
Bcl-2, Bcl-xl, and Mcl-1, than did either treatment alone
(Fig. 4b).
Caspase activation plays an important role in the clas-
sic apoptotic pathways. In this study, it was also found
that caspases 3, 6, 7, 8, and 9 and PARP were activated
by the combination treatment for 48 h (Fig. 4c). More-
over, to confirm whether HDACs, both in the single or
combination treatment, were involved in the apoptosis
pathway, the expression of HDACs and H3 acetylation
were evaluated. Vincristine (3 nM) in combination with
SAHA effectively inhibited HDAC3 and HDAC6 expres-
sion and enhanced H3 acetylation, which represents an
inhibition in HDAC activity, in a time-dependent man-
ner (Fig. 4d).
HDAC6 inhibition was involved in vincristine/SAHA-
induced apoptosis
Previous findings have shown HDAC6-induced tubulin
acetylation to affect the dynamics and function of micro-
tubules [9–12]. As shown in Fig. 5a, SAHA, a pan-
Fig. 3 SAHA-sensitized MOLT-4 cells to vincristine-mediated mitotic arrest. a Tubulin assembly was determined by an in vitro tubulin polymerization
kit and then detected by spectrophotometry. Paclitaxel (10 μM) and vincristine (10 μM) were used as positive controls. Paclitaxel is a polymerizing
agent and vincristine is a depolymerizing agent. S 5 represents SAHA 5 μM, and S 50 + V 3 represents SAHA 50 μM combined with vincristine 3 μM.
This experiment was examined in a cell-free condition. b MOLT-4 cells were treated with SAHA and vincristine alone or co-treatment for 24 h and
then stained with β-tubulin and DAPI. The immunofluorescence images were captured by the ZEISS LSM 510 META confocal microscope. All images
were under × 400 microscopic magnification. a control, b 500 nM SAHA, c 3 nM vincristine, d SAHA combined with vincristine, e 30 nM vincristine, f
30 nM paclitaxel. c Cells were treated with vincristine (0.3, 1, and 3 nM) alone or co-treated with SAHA (500 nM) for 24 h. Then, total cell lysates were
obtained to evaluate the G2/M phase regulatory protein expression and the tubulin acetylation. Data are expressed as mean values ± SD of at least
three separate determinations. S SAHA, V vincristine
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Fig. 4 Co-treatment with vincristine and SAHA induced mitochondrial membrane potential loss, caspase activation, and HDAC activity. a The
mitochondrial membrane potential was measured by the flow cytometry analysis of rhodamine 123. The MOLT-4 cells were stained with 10 μM
rhodamine 123 and incubated at 37 °C for 30 min in the presence of SAHA alone (500 nM), vincristine alone (3 nM), or coexistence of both at
different time intervals (12, 24, 36, and 48 h). The horizontal axis shows the relative fluorescence intensity and the vertical axis presents the cell
number. b MOLT-4 cells were treated with different concentrations of vincristine (0.3, 1, and 3 nM) alone, a single concentration of SAHA (500
nM) alone, and a combination with both drugs for 24 and 48 h. Then, the cell lysates were collected for western blot analysis to detect the Bcl-2
family protein levels. c Cells were incubated with vincristine and SAHA for 48 h, and caspase 3, 6, 7, 8, and 9 activations and PARP cleavage were
detected. d Similarly, the total cell lysates were analyzed to measure HDAC1, HDAC2, HDAC3, and HDAC6 expression and HDAC activity (H3 acetylation).
Data are expressed as mean values ± SD of at least three separate determinations. S SAHA, V vincristine
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bination with vincristine had no synergic effect. Tubasta-
tin A, which is a specific HDAC6 inhibitor [26], was
used to understand the role of HDAC6 in the vincris-
tine/SAHA-treated cells. To evaluate the potential bene-
fit of vincristine in combination with tubastatin A, the
cytotoxicity of co-treatment was determined and the
combination effects were analyzed. However, compared
to tubastatin A alone, vincristine significantly enhanced
the cytotoxicity of tubastatin A (Fig. 5b). Moreover, vin-
cristine (1 and 3 nM) combined with various concentra-
tions of tubastatin A induced cell accumulation at the
G2/M phase followed by the sub-G1 phase (Fig. 5c). The
CI values were <1 in combination of vincristine and
tubastatin at the G2/M phase and sub-G1 phase (Fig. 5d).
Co-treatment of vincristine and tubastatin revealed
MPM2 and PARP activation consistent with the induc-
tion of apoptosis by western blot analysis (Fig. 5e). And
vincristine and HDAC6 inhibitor combined synergism ef-
fect was further corroborated by the observation of vincris-
tine and ACY1215 co-treatment in CCRF-CEM cells
(Fig. 5f). These findings suggest that SAHA treatment may
alter microtubule dynamics in cells through HDAC6 inhib-
ition, even though the effect was insufficient to arrest cells
in the G2/M phase. However, in combination with vincris-
tine, which also had an effect on microtubules, SAHA
caused extreme microtubule stress thus causing cell death.
The antitumor activity of vincristine and SAHA
combination therapy in vivo
To evaluate whether the synergistic effect of vincristine
plus SAHA could be clinically relevant, the antitumor
activity of this co-treatment in severe combined im-
munodeficiency mice bearing established MOLT-4
tumor xenografts was investigated. Once a tumor was
palpable (approximately 100 mm3), mice were random-
ized into vehicle control and treatment groups (n = 6 per
group). All mouse tumors were allowed to reach an end-
point volume of 2000 mm3, and in vivo antitumor effi-
cacy was expressed as tumor growth delay (TGD;
Fig. 6a). There were no improvements in TGD in mice
treated with vincristine (0.1 mg/kg once weekly) or
SAHA (50 mg/kg once daily) alone. However, log-rank
analysis showed that the co-treatment exhibitedsignificant antitumor activity in the MOLT-4 xenograft
model (P = 0.0389). In addition, Kaplan–Meier curves
displayed antitumor activity for the co-treatment group
(vincristine, 0.025 mg/kg once weekly; SAHA, 200 mg/
kg once daily) (Fig. 6b). Notably, the mice tolerated all
of the treatments without overt signs of toxicity; no sig-
nificant body weight difference or other adverse side ef-
fects were observed (Fig. 6d and Additional file 5: Figure
S5). To correlate the in vivo antitumor effects with the
mechanisms identified in vitro, intratumoral biomarkers
were assessed by western blot analysis. Consistent with
in vitro results, the combined treatment markedly in-
duced caspase 3 activation and PARP cleavage in tu-
mors, indicating elevated apoptosis (Fig. 6e). Taken
together, these findings suggest that combination of vin-
cristine and SAHA, both in vitro and in vivo, dramatic-
ally enhanced vincristine-induced cell death.
Discussion
Recent preclinical studies have reported that due to their
broad anticancer potency and low toxicity, HDACis are
often used in combination therapy to enhance conven-
tional chemotherapeutic and molecular-targeted drugs.
SAHA was the first HDACi approved by the FDA for T
cell lymphoma. Moreover, vinca alkaloids have been ex-
tensively used in the clinical treatment of ALL. In spite
of their usefulness, drug resistance and neuron toxicity
remain serious clinical problems. Therefore, the purpose
of this study was to investigate the anticancer activity of
vincristine and SAHA in a T cell ALL cell line. Cytotoxic
experiments have shown that the combination of vin-
cristine and SAHA significantly induces cell death. Ana-
lyses of cell cycle and regulatory protein expressions
have indicated that co-treatment with the two drugs has
a synergistic effect on M phase arrest and is consistent
with an increase of cell numbers in the sub-G1 phase.
Furthermore, combination treatment promotes cell
apoptosis through intrinsic and extrinsic pathways. In
vivo xenograft animal models demonstrated that, com-
pared to treatment with either drug alone, vincristine in
combination with SAHA prolongs survival time in mice,
as suggested by the in vitro results.
During these studies, the level of the effects of vincris-
tine and SAHA on MOLT-4 cells was determined.
Fig. 5 (See legend on next page.)
Chao et al. Journal of Hematology & Oncology  (2015) 8:82 Page 9 of 15
(See figure on previous page.)
Fig. 5 HDAC6 was involved in vincristine/SAHA-induced cell death. a MOLT-4 cells were treated with the indicated drugs for 12 and 24 h. The cell
lysates were used to determine the HADC6 protein level and activity. b Cells were treated with tubastatin A alone, which is a specific HDAC6
inhibitor, or combined with 1 and 3 nM vincristine for 48 h. The cell viability was evaluated by MTT assay. c Cells incubated with tubastatin A
alone or in combination with the indicated concentration of vincristine for 24 and 48 h. The cell cycle distribution was measured by flow
cytometry. The figures are shown as quantitative data in the time course. d The CI value of combining tubastatin A with vincristine on G2/M and
sub-G1 phases. e Cells were treated with 10 or 20 μM tubastatin A (Tuba) alone and combined with 1 or 3 nM vincristine. The cell lysates were
used for western bolt analysis. f CCRF-CEM cells were co-treated with vincristine and ACY1215, an HDAC6-specific inhibitor, for 48 h. The CI value
of combining treatment on the sub-G1 phase
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were investigated to determine the lowest effective con-
centration of vincristine or SAHA that would provide
the maximum cytotoxic effects. It was established that
the cytotoxicity of 3 nM vincristine combined with 500
nM SAHA is much more potent in inhibiting cell sur-
vival (Fig. 1) and altering cell cycle distribution (Fig. 2)
compared to either treatment alone. A CI value smaller
than 1 at the G2/M or sub-G1 phases suggests that the
combination of vincristine and SAHA had a synergistic
action on T cell leukemic cells at certain concentrations
(Fig. 2).
Prior studies have shown that α-tubulin acetylation is
associated with microtubule dynamics and is regulated
by HDAC6 [27]. Additional research has also found
that HDACis induce microtubule acetylation and
polymerization through HDAC6 inhibition [9–12].
Whether the polymerization or the depolarization of
microtubules following the vincristine and SAHA
combination treatment was responsible for G2/M cell
cycle arrest needs to be determined for a complete
understanding of this mechanism. In vitro tubulin
polymerization assays showed that a high concentra-
tion of vincristine (10 μM) definitely caused micro-
tubule depolymerization, but a high concentration of
SAHA (50 μM) had no influence on microtubule
polymerization (Fig. 3a). However, SAHA indeed
causes the acetylation of tubulin (Figs. 4d and 5a).
These results suggest that SAHA may induce tubulin
acetylation, subsequently affecting microtubule
polymerization by inhibiting HDAC6 activity. Never-
theless, SAHA-induced polymerization was not
proven (Fig. 3a) since HDAC6 was not available in
the in vitro tubulin polymerization kits, which con-
tained only tubulin and GTP. Therefore, no SAHA-
induced polymerization effects were observed in this
assay. In addition, the literature indicates that tubulin
acetylated by certain HDACis, such as trichostatin A,
is associated with microtubule dynamics without af-
fecting the polymerization of microtubules. Therefore,
to further demonstrate the role of HDAC6, tubastatin A, a
specific HDAC6 inhibitor, was used [26–28]. Tubastatin A
and vincristine co-treatment was found to synergically in-
duce cell death and G2/M phase cell arrest, proceeding tothe sub-G1 phase, compared with tubastatin A or vincris-
tine alone (Fig. 5). These phenomena were in agreement
with the results of vincristine/SAHA combination treat-
ment. Consequently, an immunofluorescence assay was
performed to demonstrate whether microtubules were af-
fected by SAHA. Figure 3b shows that at low vincris-
tine concentrations, abnormal spindles (star-like
monopolar and multiple polars) and chromosome
disorganization were observed, as has been previously
reported by Jordan et al. [26]. However, the micro-
tubule distribution remained unchanged following
cell treatment with 500 nM SAHA. However, follow-
ing SAHA/vincristine combination treatment, more
cells were observed to have deteriorated spindles al-
though without microtubule depolymerization or
polymerization. Prior studies have shown that only
higher concentrations (>10 nM) of microtubule
agents, such as vinca alkaloids and taxol, affect
microtubule mass, but microtubule dynamics are
suppressed by low microtubule agent concentrations
(<10 nM) [4]. Taken together, vincristine/SAHA-in-
duced synergistic G2/M arrest may result from
HDAC6 inhibition-induced microtubule dynamic al-
ternation because of SAHA as well as vincristine. In
brief, vincristine and SAHA exerted a synergic action
on microtubule dynamics, albeit though different
mechanisms.
A large amount of research shows that HDACis arrest
cells in the G1 phase mainly through p21 induction.
Only a few studies mention the role of these compounds
in G2/M, and the mechanism remains uncertain. For ex-
ample, Blagosklonny et al. found that the HDACi tri-
chostatin A causes tubulin acetylation that contributes
to M phase arrest [28]. HDACis have also shown the
capability to cause immature sister chromatid separation
and slippage from the mitotic spindle assembly check-
point (SAC) [29]. Moreover, cancer cells without wild-
type p21 or p53 more easily become polyploid than
wild-type cells [30]. These results indicate that HDACi-
induced G2/M arrest is not due to an influence on tran-
scriptional activity. In contrast, other studies point out
that trichostatin A causes G2/M cell cycle arrest and
SAC slippage through an increase in p21 transcriptional
activity [31]. The mechanisms proposed above to explain
Fig. 6 The effect of vincristine and SAHA on the MOLT-4 tumor xenograft. SCID mice were ectopically implanted with MOLT-4 cells, and when
the tumor size reached 100 mm3, mice were injected with vincristine (i.p., qwk) or SAHA (p.o., qd) alone or a combination of both. a In vivo
antitumor efficacy was expressed as tumor growth delay (TGD) (vincristine 0.1 mg/kg i.v. qwk; SAHA 50 mg/kg p.o. qd). b Effects of combination
on tumor volume. The growth curves are the means of the tumor sizes measured with each group (vincristine 0.025 mg/kg i.v. qwk; SAHA
200 mg/kg p.o. qd). c The remaining percentage of mice survival (vincristine 0.1 mg/kg i.v. qwk; SAHA 50 mg/kg p.o. qd). d Effects of combined
treatment on mice body weight (vincristine 0.025 mg/kg i.v. qwk; SAHA 200 mg/kg p.o. qd). e Tumors were resected for the western blot analysis
(vincristine 0.025 mg/kg i.v. qwk; SAHA 200 mg/kg p.o. qd)
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not be excluded. We found that p21 mRNA and protein
level were elevated after treatment with vincristine or
SAHA alone and was not enhanced by combined treat-
ment (data not shown). It has been reported that all
HDACis induced p21 but differentially caused tubulin
acetylation, mitotic arrest, and cytotoxicity. Mitotic ar-
rest rather than induction of p21 determined HDACi
cytotoxicity [28]. Moreover, p21 is required for G1 arrest,
not for cell death, and is associated with resistance to
HDACi-induced apoptosis [32]. Upregulated p21 was
also found in vincristine-treated cells even though vin-
cristine caused cell arrest in the G2/M phase, leading to
apoptosis [33]. Therefore, we considered that in our
study, increased p21 expression of vincristine-SAHA
combined treatment was the cellular protection mechan-
ism for repairing damaged DNA, and this phenomenon
was not sufficient to cause apoptosis. Furthermore, vin-
cristine and SAHA did not alter p53 protein and mRNA
levels (data not shown). Consequently, the involvement
of p53 and p21 in drug-induced G2/M arrest was
eliminated.
The expression of related proteins in the M phase was
evaluated to understand the exact phase at which the
cells arrest (G2 or M). Cdc25c is a tyrosine phosphatase
that removes the inhibitory phosphorylation of Cdc2 at
Tyr15, which has already been phosphorylated on
Thr161 and contributes to Cdc2 activation. The Cdc2/
cyclin B complex then forms to move cells into the M
phase [34]. Figure 3c shows that Cdc25c and p-Tyr15
Cdc2 protein levels declined and p-Thr161 Cdc2 in-
creased following combination treatment. In addition,
expression of the M phase markers pMPM2 and H3S10
was also induced [35]. These results demonstrate that
combination treatment induces cell arrest in the M
phase and not in G2.
From the above data, we speculate that the vincristine/
SAHA combination may alter microtubule dynamics,
resulting in incorrect microtubule attachment to the
centromere of chromosomes or loss of spindle tension
across kinetochore pairs, subsequently causing SAC acti-
vation in the metaphase. An increased aurora B and PLK
kinase protein expression and aurora B kinase activity,
detected by H3S10 expression downstream of aurora B,
are shown in Fig. 3c. SAC activation inhibits anaphase-
promoting complex/cytochrome activity and decreases
cyclin B degradation to inter-anaphase to accomplish
cell division. Cells proceed to apoptosis owing to an in-
ability to repair the dysfunction [36]. Therefore, we sug-
gest that co-treatment-induced cell death was due to an
inability to repair microtubule function even if the SAC
was activated (Figs. 3c and 4c). In contrast, Dowling et al.
have found that the synergistic effect of the HDACi tri-
chostatin A and microtubule agents occurs through SACinactivation [37]. In addition, studies have shown that
HDACis induce aurora B kinase degradation and subse-
quently inactivate the SAC via HDAC3 inhibition [38].
Although HDAC3 is inhibited by 24-h vincristine and
SAHA co-treatment (Fig. 4d), the protein level of aurora
B kinase was increased (Fig. 3c). We believe that the ar-
rest at the G2/M phase does not occur through the in-
hibition of HDAC3.
Caspase activation plays a vital role in the apoptosis
pathways. Figure 4c shows that the activation of caspases
3 and 6 to 9 and PARP was synergistically induced by
vincristine combined with SAHA. This result indicates
that the combination treatment activates both the intrin-
sic and the extrinsic apoptosis pathways. Therefore, the
expression of mitochondrial proteins and mitochondrial
membrane potential were investigated. Bid is a key pro-
tein linking the extrinsic and intrinsic apoptosis path-
ways. As Fig. 4b shows, the protein level of pro-form Bid
decreased in response to co-treatment with vincristine
and SAHA. Decreases in pro-survival mitochondrial
proteins Bcl-2, Bcl-xl, and Mcl-1 also occurred. A de-
crease in mitochondrial membrane potential was signifi-
cantly induced by the combination in a time-dependent
manner.
Taking all of the above findings into consideration,
when vincristine and SAHA treatments were combined,
MOLT-4 cell survival was significantly inhibited, mainly
through the induction of M stage arrest and intrinsic
and extrinsic apoptosis pathways. Moreover, the selective
HDAC6 inhibitor exhibited similar synergism when
combined with vincristine. In vivo xenograft animal
models produced the same results as those of in vitro
models. Pan-HDAC inhibitors influenced different types
of HDACs, which caused side effects more than selective
HDAC6 inhibitors. However, the most important and
practical advantage to choose SAHA for this study is
that SAHA has been approved for cancer treatment. Se-
lective HDAC6 inhibitors such as tubastatin A and
ACY1215 are only in phase I or phase II clinical trial.
The finding of this paper not only provides another
choice for clinical treatment but also offers an idea for




The human T cell acute lymphoblastic leukemic cell
lines, MOLT-4 and CCRF-CEM, isolated from the re-
lapsed and multiresistant patients, were obtained from
Bioresource Collection and Research Center (Taiwan).
Cells were maintained in RPMI-1640 medium supple-
mented with 10 % (v/v) fetal bovine serum (Gibco BRL
Life Technologies, Grand Island, NY, USA) and 1 % of a
mixture of penicillin (100 U/ml) and streptomycin
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mek, Israel). All cells were cultured in an incubator in
the presence of 5 % CO2 at 37 °C.
Chemicals and antibodies
Vincristine and suberoylanilide hydroxamic acid (SAHA)
were purchased from Sigma Chemical Co. (St. Louis,
MO, USA), and tubastatin A (HDAC6 inhibitor) was
synthesized from Dr. Jing-Ping Liou (Taipei Medical
University, Taiwan). The above drugs were dissolved in
DMSO (dimethylsulfoxide) and then preserved at
−20 °C. Rhodamine 123, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium, propidium iodide, anti-β-
tubulin, FITC-conjugated anti-mouse IgG, and all of
the other chemical reagents used in this study were
purchased from Sigma Chemical (St. Louis, MO,
USA) and of analytical grade. Primary antibodies
against Cdc2 (pY15), aurora B, caspase 8, caspase 9,
HDAC1, HDAC2, HDAC3, HDAC4, and Bid were all
purchased from Cell Signaling Technology (Beverly,
MA); cyclin B, Cdc25C, Cdc2, PARP, Mcl-1, Bcl-2,
Bcl-xl, and secondary antibodies were purchased from
Santa Cruz (Santa Cruz, CA, USA); MPM2 (pSer/
Thr) and H3 (pS10) were purchased from Upstate
Biotechnology (Lake Placid, NY, USA); PLK (pT210), cas-
pase 6, and caspase 7 were purchased from BD Biosciences
(San Jose, CA, USA); caspase 3 was purchased from Imge-
nex (San Diego, CA, USA); acetyl-histone 3 was purchase
from Millipore (Billerica, MA, USA); and an internal con-
trol, GAPDH, was purchased from Novus Biologicals
(Littleton, CO, USA). Vectashield® mounting medium with
DAPI was purchased from Burlingame, CA, USA.
Cell viability assay
Cell viability was verified by MTT assay. Firstly, cells
were seeded in a 24-well plate at a density of 4 × 105
cells/well in 1 ml culture medium and then treated with
various concentrations of vincristine or SAHA alone or
a combination of both for 24 and 48 h. After treatment
with drugs, 100 μl MTT solution (0.5 mg/ml in
phosphate-buffered saline (PBS)) per well was added to
the 24-well plate in the dark and the plate was incubated
at 37 °C. The mitochondrial dehydrogenase of viable
cells reduced MTT (yellow) to insoluble formazan dyes
(purple). One hour later, the crystal formazan dyes were
dissolved in the extraction buffer (0.1 M sodium acetate
buffer, 100 μl/well). The absorbance was spectrophoto-
metrically analyzed at 550 nm by an ELISA reader
(Packard, Meriden, CT, USA).
Flow cytometry analysis
Evolution of the cell cycle histogram was performed by
flow cytometry analysis to detect the changes in DNA
content. Cells (1 × 106) were seeded in a 6-well plate in2 ml fresh medium and treated with graded concentra-
tions of vincristine, SAHA, or combination for the indi-
cated time. Then, cells were collected, washed with PBS
and fixed with 70 % (v/v) ice cold ethanol at −20 °C for
30 min. The fixed cells were centrifuged to remove the
ethanol, rinsed with PBS, resuspended in 0.1 ml DNA
extraction buffer (0.2 M Na2HPO4-0.1 M citric buffer,
pH 7.8) for 20 min, and subsequently stained with 500 μl
PI solution (80 μg/ml propidium iodide, 100 μg/ml RNase
A, and 1 % Triton X-100 in PBS) for 20 min at room
temperature in the dark. Data were analyzed by
FACScan Flow Cytometer and CellQuest software
(Becton Dickinson).
In vitro tubulin polymerization assay
To determine the microtubule polymerization of the in-
dicated drugs in a cell-free condition, CytoDYNAMIX
Screen 03 Kit (Cytoskeleton Inc.) was performed. Gen-
eral tubulin buffer, GTP stock (100 mM), and tubulin
protein (10 mg/ml) were all prepared well following the
protocol. A 96-well plate was placed in the spectropho-
tometer to prewarm at 37 °C for 30 min before detec-
tion. Then preparing the iced tubulin polymerization
(TP) buffer, all mentioned processes were needed on the
ice. Next, the drugs (2 μl) were added into each Eppen-
dorf included with 85 μl TP buffer. The drugs must in-
clude DMSO (the control group), paclitaxel (10 μΜ),
and vincristine (10 μΜ). Paclitaxel and vincristine were
used as positive controls. Paclitaxel would induce the
microtubule polymerization; in contrast, vincristine
would depolymerize the microtubules. Finally, 30 μl
tubulin proteins was added into the Eppendorf and
transferred to the prewarmed 96-well plate. The absorb-
ance was measured by a spectrophotometer and re-
corded every 1 min for 30 min at 340 nm and 37 °C.
Immunofluorescence analysis
Microtubule distribution and morphology were detected
by immunofluorescence. Cover slides were placed in the
24-well plate and coated with poly-D-lysine for 1 day at
least to enhance the suspension cells attached to the
cover slides. Cells were seeded into the 24-well plate
(8 × 105 cells/well) and treated with vincristine, SAHA,
or both drugs for 24 h. The following experiments were
performed at room temperature. The cells were fixed
with 8 % paraformaldehyde in PBS for 15 min. After
washing with PBS for several times, the cells were
permeabilized with 0.1 % Triton X-100 in PBS for
10 min. Then, the cells were rinsed with PBS for 10 min
three times. For blocking, 3 % BSA in PBS was used.
After 1 h, the cells were washed with PBS and incubated
with a primary β-tubulin antibody (1:200) for 2 h and
FITC-conjugated anti-mouse IgG antibody (1:200) for
2 h. The mounting medium, which contains DAPI stain,
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covered to the slides. Images were detected and captured
with the ZEISS LSM 510 META confocal microscope.
Western blot analysis
After the treatment, cells (106 cells/ml) were harvested.
Whole cell pellets were washed twice with PBS, lysed in
lysis buffer (50 mM Tris, pH 7.4; 150 mM NaCl; 1 % Tri-
ton X-100; 1 mM EDTA; 1 mM EGTA) supplemented
with protease inhibitors (1 mM PMSF, 10 μg/ml aprotinin,
10 μg/ml leupeptin, 1 mM sodium orthovanadate, and
1 mM NaF) for 30 min, and then centrifuged for 30 min
at 13,000 rpm at 4 °C. Total protein content was quanti-
fied by BCA Protein Assay Kit (Thermo Fisher Scientific,
Rockford, IL, USA). Equivalent amounts of proteins were
separated into diverse percentages by SDS-PAGE and sub-
sequently transferred onto PVDF membranes. The mem-
branes were blocked with 5 % nonfat milk in PBS for 1 h
at room temperature and incubated with primary antibody
in PBST buffer (0.1 % Tween 20 in PBS) at 4 °C overnight.
After washing the membranes with PBST, blots were de-
veloped with the corresponding HRP-conjugated second-
ary antibody diluted in 0.5 % nonfat milk in PBS for 1 h at
room temperature. The membrane was washed frequently
with PBST, and finally immunoreactive protein bands
were displayed using an enhanced chemiluminescence de-
tection kit (Amersham, Buckinghamshire, UK).
Mitochondrial membrane potential
Rhodamine 123 was used to evaluate mitochondrial
membrane potential. Rhodamine 123 is a kind of cat-
ionic fluorescent dye, which localizes in the mitochon-
dria. Loss of mitochondrial membrane potential is
associated with a lack of rhodamine 123 retention and a
decrease of fluorescence intensity. Cells were treated
with vincristine, SAHA, or combination for the indicated
time. Rhodamine 123 (final concentration 10 μM) was
added and incubated for 30 min at 37 °C in the dark.
Then, cells were harvested and rinsed with PBS. The
fluorescence intensity was measured by FACScan Flow
Cytometer and CellQuest software (Becton Dickinson).
Tumor xenograft model
A tumor xenograft model was used to estimate the
combination effect of vincristine and SAHA in vivo.
MOLT-4 cells were implanted (107 cells/ml) into se-
vere combined immunodeficiency (SCID) mice. When
the average tumor size reached 100 mm3, mice were
treated with an indicated dosage of vincristine or
SAHA alone or a combination of both. Mice were
scarified until the average tumor size was larger than
2500 mm3. Then, tumors were resected and frozen
for the western blot analysis to evaluate the effect of
vincristine/SAHA combination in vivo. All animalexperiments followed ethical standards, and protocols
have been reviewed and approved by the Animal Use
and Management Committee of National Taiwan Uni-
versity (IACUC Approval No.: 20100225).
Statistical analysis
All experiments were done independently three times
and presented as mean values ± SD, and then assessed
by Bonferroni’s t test. The animal experiments were de-
termined by the Mann-Whitney test. P < 0.05 was con-
sidered statistically significant.
Additional files
Additional file 1: Figure S2. The effect of vincristine and SAHA
co-treatment in acute myeloid leukemic cell lines. (A) HL60 (acute
promyelocytic leukemia) cells were co-treated with the indicated
vincristine and SAHA, and the CI values of the sub-G1 phase were
analyzed. (B) The cell viability of U937 (acute monocytic leukemia)
after the indicated treatment. V, vincristine; S, SAHA; Tuba,
tubastatin A.
Additional file 2: Figure S1. The effect of vincristine combined with
various doses of SAHA. (A) MOLT-4 cells were treated with various
SAHA alone or combined with 1 and 3 nM vincristine for 48 h. The
cell viability was evaluated by MTT assay. (B) The distribution of cell
cycle after MOLT-4 cells were treated with various concentrations of
SAHA alone or in combination with vincristine 1 or 3 nM for 24 and
48 h. The quantitative data are shown in the time course. (C) The
combination effect on G2/M arrest (left figure) and apoptosis (right
figure) were used by the combination index (CI).
Additional file 3: Figure S3. The results of vincristine- (0.3 and 3 μM),
or SAHA (5 and 50 μM) alone, or combination of both in vitro tubulin
polymerization assay. (A) The figure shows more comprehensive results
on in vitro tubulin polymerization, including paclitaxel (10 μM), vincristine
(0.3, 3, and 10 μM), SAHA (S, 5 and 10 μM) alone, and SAHA combined
with vincristine (S 50 + V 0.3 and S 5 + V3). (B) The absorbance of
different drugs at the endpoint (30 min).
Additional file 4: Figure S4. The quantity of abnormal spindles in
vincristine alone compared to combination with SAHA. MOLT-4 cells were
treated with SAHA (0.5 μM) and vincristine alone (3 nM) or co-treatment for
24 h and then stained with β-tubulin and DAPI. The figure shows the
quantity of abnormal spindles by the immunofluorescence images.
Additional file 5: Figure S5. The cell toxicity of normal cells after
combination treatment. The cell viability (MTT assay) of (A) HUVEC
(human umbilical vein endothelial cell) and (B) BEAS-2B (human bronchial
epithelial cell) after co-treating with the indicated drugs for 48 h.
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